Phosphorylation-Mediated Activation of β-Catenin-TCF4-CEGRs/ALCDs Pathway Is an Essential Event in Development of Aggressive Hepatoblastoma.
epigenetics
hepatoblastoma
liver cancer
β-catenin
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Dec 2022
09 Dec 2022
Historique:
received:
14
11
2022
revised:
01
12
2022
accepted:
04
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Hepatoblastoma (HBL), a deadly malignancy in children, is the most common type of pediatric liver cancer. We recently demonstrated that β-catenin, phosphorylated at S675 (ph-S675-β-catenin), causes pathological alterations in fibrolamellar hepatocellular carcinoma (FLC), by activating oncogenes and fibrotic genes via human genomic regions, known as cancer-enhancing genomic regions or aggressive liver cancer domains (CEGRs/ALCDs). The aim of this study was to determine the role of the ph-S675-β-catenin-TCF4-CEGRs/ALCDs pathway in HBL. The ph-S675-β-catenin-TCF4-CEGRs/ALCDs pathway was examined in a large cohort of HBL specimens, in HBL cell lines HepG2 and Huh6, and in patient-derived xenografts (PDXs). β-catenin is phosphorylated at S675 in a large portion of tested HBL patients. In these patients, ph-S675-β-catenin forms complexes with TCF4 and opens CEGRs/ALCDs-dependent oncogenes for transcription, leading to a massive overexpression of the oncogenes. The inhibition of the β-catenin-TCF4-CEGRs/ALCDs axis inhibits the proliferation of cancer cells and tumor growth in HBL cell lines and HBL-PDXs. The ph-S675-β-catenin is abundant in mitotic cells. We found that markers of HBL Glypican 3 ( The phosphorylation-mediated activation of the β-catenin-TCF4-p300-CEGRs/ALCDs pathway increases oncogene expression in patients with aggressive liver cancer and promotes the development of hepatoblastoma.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Hepatoblastoma (HBL), a deadly malignancy in children, is the most common type of pediatric liver cancer. We recently demonstrated that β-catenin, phosphorylated at S675 (ph-S675-β-catenin), causes pathological alterations in fibrolamellar hepatocellular carcinoma (FLC), by activating oncogenes and fibrotic genes via human genomic regions, known as cancer-enhancing genomic regions or aggressive liver cancer domains (CEGRs/ALCDs). The aim of this study was to determine the role of the ph-S675-β-catenin-TCF4-CEGRs/ALCDs pathway in HBL.
METHODS
METHODS
The ph-S675-β-catenin-TCF4-CEGRs/ALCDs pathway was examined in a large cohort of HBL specimens, in HBL cell lines HepG2 and Huh6, and in patient-derived xenografts (PDXs).
RESULTS
RESULTS
β-catenin is phosphorylated at S675 in a large portion of tested HBL patients. In these patients, ph-S675-β-catenin forms complexes with TCF4 and opens CEGRs/ALCDs-dependent oncogenes for transcription, leading to a massive overexpression of the oncogenes. The inhibition of the β-catenin-TCF4-CEGRs/ALCDs axis inhibits the proliferation of cancer cells and tumor growth in HBL cell lines and HBL-PDXs. The ph-S675-β-catenin is abundant in mitotic cells. We found that markers of HBL Glypican 3 (
CONCLUSIONS
CONCLUSIONS
The phosphorylation-mediated activation of the β-catenin-TCF4-p300-CEGRs/ALCDs pathway increases oncogene expression in patients with aggressive liver cancer and promotes the development of hepatoblastoma.
Identifiants
pubmed: 36551548
pii: cancers14246062
doi: 10.3390/cancers14246062
pmc: PMC9775972
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK078392
Pays : United States
Références
Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1578-85
pubmed: 17332475
Cell Death Dis. 2020 Oct 2;11(10):822
pubmed: 33009373
Cancers (Basel). 2021 Apr 12;13(8):
pubmed: 33921282
J Hepatol. 2022 Oct;77(4):1026-1037
pubmed: 35577029
Hepatology. 2021 Oct;74(4):2201-2215
pubmed: 34037269
J Hepatol. 2019 Jan;70(1):108-117
pubmed: 30287339
Hepatol Commun. 2022 Oct;6(10):2950-2963
pubmed: 36000549
J Hepatol. 2014 Dec;61(6):1312-20
pubmed: 25135868
Cell Mol Gastroenterol Hepatol. 2021;12(5):1669-1682
pubmed: 34245919
Commun Biol. 2018 Jun 11;1:67
pubmed: 30271949
Cancer. 2022 Jul 15;128(14):2786-2795
pubmed: 35561331
Pediatr Dev Pathol. 2020 Mar-Apr;23(2):79-95
pubmed: 31554479
Evid Based Complement Alternat Med. 2022 Jul 31;2022:2417134
pubmed: 35958911
Oncol Lett. 2018 Jul;16(1):970-976
pubmed: 29963171
Cancer Cell. 2008 Dec 9;14(6):471-84
pubmed: 19061838
Sci Rep. 2017 Apr 05;7:45932
pubmed: 28378832
Am J Pathol. 2019 May;189(5):1091-1104
pubmed: 30794807
EBioMedicine. 2022 Jun;80:104069
pubmed: 35605429
Int J Oncol. 2019 Oct;55(4):775-788
pubmed: 31432151
Carcinogenesis. 2017 Jul 1;38(7):738-747
pubmed: 28535186
Nucleic Acids Res. 2010 Sep;38(17):5735-45
pubmed: 20460455
EBioMedicine. 2017 Sep;23:79-87
pubmed: 28844410
Oncogene. 2006 Jan 26;25(4):599-608
pubmed: 16314847
Clin Biochem. 2020 May;79:54-60
pubmed: 32087138
J Biol Chem. 2019 Nov 15;294(46):17524-17542
pubmed: 31597698
Gastroenterology. 2022 Aug;163(2):481-494
pubmed: 35489428
Pediatr Blood Cancer. 2019 Jul;66(7):e27745
pubmed: 30977242
Am J Pathol. 2009 Sep;175(3):1056-65
pubmed: 19679878
Arch Stem Cell Ther. 2021;2(1):1-4
pubmed: 34447970
Cancers (Basel). 2022 Apr 10;14(8):
pubmed: 35454818